Sequencing HER2 ADCs by payload after T-DXd
When Enhertu stops working, the next ADC should probably carry a different kind of payload, such as the tubulin inhibitors in Kadcyla or ARX788, rather than another topoisomerase drug.
T-DXd is now used first line and in early disease, so most later-line HER2 ADC use will follow T-DXd. Resistance often spares HER2 expression but involves TOP1/SLFN11 changes; tubulin-payload ADCs (T-DM1, ARX788, disitamab vedotin) or HER2 TKIs may retain activity.
Pages like this
not linked directly; found by shared links- PairingCaution: TOP1 ADC immediately after TOP1 ADC
Shares Sequential multiple-assignment randomised trials to find the best order of ADCs, ADC sequencing, Trastuzumab deruxtecan.
- TrialDESTINY-Breast05
Shares Trastuzumab emtansine, Trastuzumab deruxtecan, HER2-positive breast cancer.
- ProductTrastuzumab duocarmazine
Shares Trastuzumab deruxtecan, HER2-positive breast cancer, Antibody-drug conjugate (ADC).
- TrialACE-Breast-02
Shares ARX788, HER2-positive breast cancer.
- PersonSara A. Hurvitz
Shares Trastuzumab emtansine, Trastuzumab deruxtecan, HER2-positive breast cancer, Antibody-drug conjugate (ADC).
- CompanyRemeGen
- TrialHER2CLIMB-02
- PersonKan Yonemori
Shares Trastuzumab deruxtecan, HER2-positive breast cancer, Antibody-drug conjugate (ADC).